BUSINESS

• Espha President Signals Move Toward Novel Drug Development amid Group Shift
  July 11, 2025

• Izervay US Sales Reach 15.9 Billion Yen in April-June: Astellas
  July 11, 2025

• Taiho’s DMD Drug TAS-205 Falls Short in PIII Trial
  July 9, 2025

• JCR Licenses Gene Therapy Platform to Alexion
  July 9, 2025

• Japan’s CAR-T Market Set to Double by 2030, Hitting 39 Billion Yen: Fuji Keizai
  July 9, 2025

• Japan Ethical Drug Sales Up 0.5% in May: Crecon
  July 9, 2025

• ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
  July 9, 2025

• Fujifilm to Offer Small-Batch CDMO Services for Investigational mRNA Drugs from 2026
  July 8, 2025

• Chugai, Gero Ink Joint Research on Aging-Related Diseases
  July 8, 2025

• Nxera Earns US$4.8 Million Milestone as Centessa’s OX2R Drug Advances
  July 7, 2025

• Keytruda Tops Japan Drug Ranking for 21st Month: Encise
  July 7, 2025

• Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
  July 3, 2025

• Nippon Shinyaku Strikes Research Pact with Boston Children’s Hospital
  July 2, 2025

• BeiGene Japan Rebrands as BeOne, Debuts PD-1 Inhibitor Tevimbra
  July 2, 2025

• ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
  July 2, 2025

• Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
  July 2, 2025

• Tavalisse Now Available in South Korea for Chronic ITP: Kissei
  July 2, 2025

• Ono Targets over 800 Billion Yen in FY2035 Sales under Growth Scenario: CEO
  July 1, 2025

• SymBio Seeks EU Clearance to Launch Global PIII Trial of Brincidofovir
  July 1, 2025

• Glaucoma Drug Gla-Alpha Approved in Singapore: Kowa
  July 1, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 44
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• …
• Next ›
• 最終 »